Human Umbilical Cord Mesenchymal Stem Cells Treatment in Sepsis

Recruiting Early Phase 1 Interventional Study
Sepsis
No Placebo Group Every participant receives an active treatment — no one gets a placebo.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
0 – 65
Sex
Any
Trial phase
Early Phase 1
Study type
Interventional
Purpose
Treatment
Participants needed
180 (estimated)
Sponsor
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
The primary objective: To evaluate the efficacy of intravenous infusion of universal UC-MSCs and CD83+MSCs subpopulation injection in the treatment of sepsis by using the 28-day survival rate of the subjects as the primary efficacy criterion.The secondary objectives: 1. To systematically evaluate the safety of universal UC-MSCs and CD83+MSCs subpopulation in the treatment of sepsis; 2. To provide …
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: * Age: 0-65 years old, diagnosed with sepsis * Clinical diagnosis of sepsis (based on Sepsis 3.0 International Guidelines) * Confirmed or suspected infection Exclusion Criteria: * Violation of medical ethics * Significant confounding factors likely to bias study outcomes * Poo…
Contacts

Xiang Xu, Professor

+8613637843870

xiangxu@tmmu.edu.cn

CONTACT